Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 12:20PM ET
41.56
Dollar change
+0.23
Percentage change
0.56
%
IndexRUT P/E- EPS (ttm)-6.50 Insider Own14.26% Shs Outstand68.00M Perf Week-4.13%
Market Cap2.83B Forward P/E- EPS next Y-5.90 Insider Trans-0.11% Shs Float58.38M Perf Month-9.53%
Income-367.30M PEG- EPS next Q-1.43 Inst Own89.44% Short Float13.57% Perf Quarter-1.82%
Sales78.50M P/S36.04 EPS this Y11.89% Inst Trans-1.08% Short Ratio10.51 Perf Half Y103.73%
Book/sh9.71 P/B4.28 EPS next Y-1.21% ROA-28.55% Short Interest7.92M Perf Year58.93%
Cash/sh18.60 P/C2.23 EPS next 5Y- ROE-59.97% 52W Range13.57 - 53.08 Perf YTD0.97%
Dividend Est.- P/FCF- EPS past 5Y23.62% ROI-55.54% 52W High-21.70% Beta1.95
Dividend TTM- Quick Ratio4.98 Sales past 5Y80.30% Gross Margin91.46% 52W Low206.26% ATR (14)2.18
Dividend Ex-Date- Current Ratio4.98 EPS Y/Y TTM-22.31% Oper. Margin-511.46% RSI (14)40.36 Volatility3.74% 5.16%
Employees445 Debt/Eq0.01 Sales Y/Y TTM-36.59% Profit Margin-467.90% Recom1.26 Target Price68.59
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q-62.59% Payout- Rel Volume0.30 Prev Close41.33
Sales Surprise-189.17% EPS Surprise-112.82% Sales Q/Q-213.42% EarningsFeb 27 BMO Avg Volume754.17K Price41.56
SMA20-6.79% SMA50-6.62% SMA20037.82% Trades Volume104,900 Change0.56%
Date Action Analyst Rating Change Price Target Change
Feb-28-24Reiterated Oppenheimer Outperform $95 → $80
Feb-14-24Downgrade Citigroup Buy → Neutral $36 → $55
Feb-01-24Initiated Goldman Buy $70
Dec-19-23Upgrade Wells Fargo Equal Weight → Overweight $25 → $63
Dec-06-23Upgrade Jefferies Hold → Buy $40
Nov-20-23Upgrade Guggenheim Neutral → Buy
Oct-23-23Upgrade Wedbush Neutral → Outperform $27 → $24
Jun-26-23Resumed Oppenheimer Outperform $95
Jan-12-23Downgrade Guggenheim Buy → Neutral
Jan-03-23Downgrade Wells Fargo Overweight → Equal Weight $83 → $49
Mar-18-24 04:40PM
Mar-04-24 07:00AM
Feb-28-24 08:30AM
Feb-27-24 08:30AM
07:00AM
09:55AM Loading…
Feb-23-24 09:55AM
Feb-21-24 12:00PM
Feb-20-24 04:05PM
07:00AM
Feb-14-24 08:00AM
Feb-08-24 08:26AM
Feb-06-24 09:55AM
06:45AM
Feb-02-24 02:59AM
Feb-01-24 04:30PM
12:00PM Loading…
Jan-17-24 12:00PM
Jan-16-24 05:01PM
Jan-01-24 09:55AM
09:40AM
Dec-27-23 05:03AM
Dec-25-23 09:55AM
Dec-18-23 02:58PM
Dec-15-23 09:40AM
Dec-05-23 10:52PM
01:33PM
Dec-01-23 09:55AM
Nov-28-23 05:05PM
Nov-27-23 07:00AM
Nov-15-23 09:55AM
Nov-13-23 09:55AM
08:02AM Loading…
Nov-07-23 08:02AM
07:00AM
Nov-02-23 07:00AM
Oct-31-23 07:39AM
Oct-22-23 07:00AM
Oct-18-23 07:00AM
Oct-15-23 06:07PM
06:05PM
Sep-01-23 07:00AM
Aug-16-23 10:54AM
Aug-10-23 07:06AM
06:02AM
Aug-08-23 09:05AM
07:00AM
Jul-31-23 04:30PM
Jul-06-23 09:00AM
Jun-28-23 08:29PM
Jun-17-23 08:57AM
Jun-15-23 04:30PM
Jun-13-23 04:51AM
Jun-08-23 01:05PM
07:00AM
Jun-05-23 07:00AM
May-08-23 07:00AM
May-07-23 08:04AM
May-05-23 08:35AM
07:00AM
May-03-23 07:00AM
May-02-23 01:00PM
Apr-21-23 04:00PM
Apr-17-23 08:01AM
Apr-14-23 03:32AM
Apr-03-23 07:00AM
Feb-27-23 04:00PM
Feb-24-23 05:10AM
05:10AM
Feb-23-23 08:45AM
07:00AM
Feb-06-23 04:30PM
Jan-28-23 01:30PM
Jan-11-23 08:35AM
Jan-04-23 07:00AM
Jan-03-23 07:11AM
Dec-16-22 09:00AM
Nov-25-22 04:04AM
Nov-22-22 11:20AM
07:12AM
Nov-08-22 08:15AM
07:00AM
Nov-01-22 04:00PM
08:32AM
Oct-27-22 11:04AM
07:00AM
Oct-03-22 07:00AM
Sep-30-22 09:00AM
Sep-26-22 07:00AM
Sep-13-22 10:17AM
Aug-31-22 07:00AM
Aug-18-22 04:01PM
Aug-15-22 09:13AM
07:00AM
Aug-04-22 08:35AM
07:00AM
Aug-01-22 07:00AM
Jul-27-22 07:12AM
Jul-06-22 04:10PM
Jun-27-22 08:52AM
Jun-02-22 04:00PM
Jun-01-22 08:00AM
May-10-22 08:26AM
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Houston John GPresident and CEOFeb 23 '24Sale47.055,196244,4721,036,681Feb 27 06:35 PM
Cassidy Sean AChief Financial OfficerFeb 23 '24Sale47.051,70280,079181,916Feb 27 06:34 PM
Taylor IanChief Scientific OfficerFeb 23 '24Sale47.051,70180,032147,522Feb 27 06:33 PM
Peck RonaldChief Medical OfficerFeb 23 '24Sale47.051,69979,93867,516Feb 27 06:34 PM
Taylor IanChief Scientific OfficerJan 04 '24Option Exercise16.008,252132,032109,973Jan 08 04:39 PM
Peck RonaldChief Medical OfficerAug 11 '23Sale24.391,32432,28929,965Aug 14 05:27 PM